Iranian Journal of Pathology

Frequency of Human Papillomavirus Genotypes among Women with Genital Wart Using Molecular Hybridization Methods

Document Type : Original Research

Authors

Zahra Shahriyari 1
Zahra Soleimani 1
Mohammad Niakan 2

1 Department of Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran

2 Department of Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran.

https://doi.org/10.30699/ijp.2024.2013097.3182
Abstract
Background & Objective: Human papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide, which can lead to virus-related cancers. This study aimed to investigate the frequency of HPV genotypes in women with genital warts referred to available laboratories in Tehran by molecular hybridization method.
Methods: This cross-sectional descriptive study was conducted on the genital warts of 67 women aged 20-50, who were referred to the clinics of Afshar, Namad, Mani, and Al-Mohammed in Tehran province. Viral DNA was extracted using Add prep genomic DNA extraction kit, and genotyping was studied using HPV Direct Flow CHIP Kit.  Data were analyzed by GraphPad Prism software.  
Results: HPV was reported to be positive in all cases. The most common low-risk genotype involved was type 6, with 30 cases (44.77%), and the most common high-risk genotype involved was type 16, with 4 cases (5.97%) in the total population. Among the patients examined, there were 16 cases with multiple infections.
Conclusion: The results of this study showed that low-risk genotypes may be responsible for majority of the genital warts. High-risk genotypes and simultaneous infection with several genotypes could also be common in genital wart samples. Therefore, controlling HPV infection is important, especially in patients with high-risk genotypes. HPV genotyping should be considered in diagnosis and prevention of  HPV-related cancers. 

Keywords

Human papillomavirus
Genotype distribution
Genital warts
Molecular hybridization

Subjects

  1. Fazlalipour M, Ghoreshi Z-a-s, Molaei HR, Arefinia N. The role of DNA viruses in human cancer. Cancer Informatics. 2023;22:11769351231154186.[PMCID] [DOI:10.1177/11769351231154186] [PMID]
  2. Roman BR, Aragones A. Epidemiology and incidence of HPV-related cancers of the head and neck. J Surg Oncol. 2021;124(6):920-2. [DOI:10.1002/jso.26687] [PMID] [PMCID]
  3. Soheili M, Keyvani H, Soheili M, Nasseri S. Human papilloma virus: A review study of epidemiology, carcinogenesis, diagnostic methods, and treatment of all HPV-related cancers. Medical journal of the Islamic Republic of Iran. 2021;35:65. [DOI:10.47176/mjiri.35.65] [PMID] [PMCID]
  4. Bitarafan F, Hekmat MR, Khodaeian M, Razmara E, Ashrafganjoei T, Gilani MM, et al. Prevalence and genotype distribution of human papillomavirus infection among 12 076 Iranian women. International Journal of Infectious Diseases. 2021;111:295-302. [DOI:10.1016/j.ijid.2021.07.071] [PMID]
  5. Hajibagheri K, Abaszade A, Afrasiabian S, Verdi F, Roshani D, Abdi F, et al.: Frequency of human papilloma virus genotypes Among woman with genitalia lesion, Sanandaj, Iran. Scientific Journal of Kurdistan University of Medical Sciences. 2018;23(4):46-52.
  6. Yu M, Chi X, Huang S, Wang Z, Chen J, Qian C, et al. A bacterially expressed triple-type chimeric vaccine against human papillomavirus types 51, 69, and 26. Vaccine. 2022;40(42):6141-52. [DOI:10.1016/j.vaccine.2022.09.010] [PMID]
  7. Ferris DG, Brown DR, Giuliano AR, Myers E, Joura EA, Garland SM, et al. Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial. Papillomavirus Res. 2020;10:100202. [DOI:10.1016/j.pvr.2020.100202] [PMID] [PMCID]
  8. Kojima A, Maeda H, Sugita Y, Tanaka S, Kameyama Y. Human papillomavirus type 38 infection in oral squamous cell carcinomas. Oral Oncol. 2002;38(6): 591-6. [DOI:10.1016/S1368-8375(01)00112-9] [PMID]
  9. Moniri Javadhesari S, Pourseif S, Khakpour K. Nucleic acid vaccines for human papillomavirus; prevention or treatment. The Iranian Journal of Obstetrics, Gynecology and Infertility. 2019;22(7):77-88.
  10. Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ. 2007;85(9):719-26. [DOI:10.2471/BLT.06.038414] [PMID] [PMCID]
  11. Di Donato V, Caruso G, Petrillo M, Kontopantelis E, Palaia I, Perniola G, et al. Adjuvant HPV Vaccination to Prevent Recurrent Cervical Dysplasia after Surgical Treatment: A Meta-Analysis. Vaccines (Basel). 2021;9(5):410. [DOI:10.3390/vaccines9050410] [PMID] [PMCID]
  12. Prati B, Marangoni B, Boccardo E. Human papillomavirus and genome instability: from productive infection to cancer. Clinics (Sao Paulo). 2018;73(suppl 1):e539s. [DOI:10.6061/clinics/2018/e539s] [PMID] [PMCID]
  13. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9(5):425-34. [DOI:10.1016/S1470-2045(08)70103-7] [PMID]
  14. Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A, et al. NORDCAN--a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49(5):725-36. [DOI:10.3109/02841861003782017] [PMID]
  15. Pimple S, Mishra G. Cancer cervix: Epidemiology and disease burden. Cytojournal. 2022;19:21.[PMCID] [DOI:10.25259/CMAS_03_02_2021] [PMID]
  16. Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Moller H, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev. 2005;14(3):677-86. [DOI:10.1158/1055-9965.EPI-04-0569] [PMID]
  17. Yuan J, Ni G, Wang T, Mounsey K, Cavezza S, Pan X, et al. Genital warts treatment: Beyond imiquimod. Hum Vaccin Immunother. 2018;14(7):1815-9. [DOI:10.1080/21645515.2018.1445947] [PMID] [PMCID]
  18. Mutombo AB, Benoy I, Tozin R, Bogers J, Van Geertruyden JP, Jacquemyn Y. Prevalence and Distribution of Human Papillomavirus Genotypes Among Women in Kinshasa, The Democratic Republic of the Congo. J Glob Oncol. 2019;5:1-9. [DOI:10.1200/JGO.19.00110] [PMID] [PMCID]
  19. Bogani G, Leone Roberti Maggiore U, Signorelli M, Martinelli F, Ditto A, Sabatucci I, et al. The role of human papillomavirus vaccines in cervical cancer: Prevention and treatment. Crit Rev Oncol Hematol. 2018;122:92-7. [DOI:10.1016/j.critrevonc.2017.12.017] [PMID]
  20. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30 Suppl 5:F12-23. [DOI:10.1016/j.vaccine.2012.07.055] [PMID]
  21. Araldi RP, Sant'Ana TA, Modolo DG, de Melo TC, Spadacci-Morena DD, de Cassia Stocco R, et al. The human papillomavirus (HPV)-related cancer biology: An overview. Biomed Pharmacother. 2018;106:1537-56. [DOI:10.1016/j.biopha.2018.06.149] [PMID]
  22. Dogan S, Terzioglu E, Ucar S. Innate immune response against HPV: Possible crosstalking with endocervical gammadelta T cells. J Reprod Immunol. 2021;148: 103435. [DOI:10.1016/j.jri.2021.103435] [PMID]
  23. Ghoreshi Z-a, Nakhaee M, Samie M, Zak MS, Arefinia N. Innate immune sensors for detecting nucleic acids during infection. Journal of Laboratory Medicine. 2022;46(3):155-64. [DOI:10.1515/labmed-2021-0173]
  24. Yan X, Shen L, Xiao Y, Wang Q, Li F, Qian Y. Prevalence, characteristics, and distribution of HPV genotypes in women from Zhejiang Province, 2016-2020. Virol J. 2021;18(1):208. [DOI:10.1186/s12985-021-01676-z] [PMID] [PMCID]
  25. Molano M, Posso H, Weiderpass E, Van den Brule A, Ronderos M, Franceschi S, et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. 2002;87(3):324-33. [DOI:10.1038/sj.bjc.6600442] [PMID] [PMCID]
  26. Arena S, Marconi M, Ubertosi M, Frega A, Arena G, Villani C. HPV and pregnancy: diagnostic methods, transmission and evolution. Minerva Ginecol. 2002;54(3):225-37.
  27. Tommasino M, editor The human papillomavirus family and its role in carcinogenesis. Seminars in cancer biology; 2014: Elsevier. [DOI:10.1016/j.semcancer.2013.11.002] [PMID]
  28. Tranberg M, Jensen JS, Bech BH, Andersen B. Urine collection in cervical cancer screening - analytical comparison of two HPV DNA assays. BMC Infect Dis. 2020;20(1):926. [DOI:10.1186/s12879-020-05663-7] [PMID] [PMCID]
  29. Chen Z, Meng W, Du R, Zhu Y, Zhang Y, Ding Y. Genotype distribution and the relative risk factors for human papillomavirus in Urumqi, China. Exp Ther Med. 2013;6(1):85-90. [DOI:10.3892/etm.2013.1073] [PMID] [PMCID]
  30. Jamdar F, Farzaneh F, Navidpour F, Younesi S, Balvayeh P, Hosseini M, et al. Prevalence of human papillomavirus infection among Iranian women using COBAS HPV DNA testing. Infectious agents and cancer. 2018;13(1):1-5. [DOI:10.1186/s13027-018-0178-5] [PMID] [PMCID]
  31. Kesheh MM, Keyvani H. The prevalence of HPV genotypes in Iranian population: An Update. Iran J Pathol. 2019;14(3):197.[PMID] [PMCID] [DOI:10.30699/IJP.2019.90356.1861]
  32. Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A. Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination-Review of Current Perspectives. J Oncol. 2019;2019:3257939. [DOI:10.1155/2019/3257939] [PMID] [PMCID]
  33. Hassani S, Nadji PS, Mohseni A, Rahnamaye Farzami M, Mirab Samiee S, Sadr M, et al. Evaluation Frequency of Human Papillomavirus and Its Related Genotypes in Women of the General Population Living in 11 Provinces of Iran. Can J Infect Dis Med Microbiol. 2022;2022:8668557. [DOI:10.1155/2022/8668557] [PMID] [PMCID]
  34. Ashaka OS, Omoare AA, James AB, Adeyemi OO, Oladiji F, Adeniji KA, et al. Prevalence and Risk Factors of Genital Human Papillomavirus Infections among Women in Lagos, Nigeria. Tropical Medicine and Infectious Disease. 2022;7(11):386. [DOI:10.3390/tropicalmed7110386] [PMID] [PMCID]
  35. Taghizadeh E, Taheri F, Abdolkarimi H, Ghorbani Renani P, Gheibi Hayat SMJI. Distribution of human papillomavirus genotypes among women in Mashhad, Iran. 2017;60(1-2):38-42. [DOI:10.1159/000477848] [PMID]
  36. Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda GA, Zhou Y, et al. Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation. Front Public Health. 2020;8:552028. [DOI:10.3389/fpubh.2020.552028] [PMID] [PMCID]
  37. Coser J, Boeira Tda R, Wolf JM, Cerbaro K, Simon D, Lunge VR. Cervical human papillomavirus infection and persistence: a clinic-based study in the countryside from South Brazil. Braz J Infect Dis. 2016;20(1):61-8. [DOI:10.1016/j.bjid.2015.10.008] [PMID] [PMCID]
  38. Aljunid S, Zafar A, Saperi S, Amrizal M. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination. Asian Pac J Cancer Prev. 2010;11(6):1551-9.
  39. Trottier H, Franco EL. Human papillomavirus and cervical cancer: burden of illness and basis for prevention. Am J Manag Care. 2006;12(17 Suppl): S462-72.
  40. Shalchimanesh Z, Ghane M, Kalantar E. Prevalence of Human Papillomavirus Genotypes in Tehran, Iran. J Res Health Sci. 2022;22(3):e00553. [DOI:10.34172/jrhs.2022.88] [PMID] [PMCID]
  41. Sabet F, Mosavat A, Ahmadi Ghezeldasht S, Basharkhah S, Shamsian SAA, Abbasnia S, et al. Prevalence, genotypes and phylogenetic analysis of human papillomaviruses (HPV) in northeast Iran. Int J Infect Dis. 2021;103:480-8. [DOI:10.1016/j.ijid.2020.12.015] [PMID]
  42. Wang J, Tang D, Wang J, Zhang Z, Chen Y, Wang K, et al. Genotype distribution and prevalence of human papillomavirus among women with cervical cytological abnormalities in Xinjiang, China. 2019. [DOI:10.1080/21645515.2019.1578598] [PMID] [PMCID]
  43. Wu J, Li X, Liu X, Gao Z. Human papillomavirus genotype prevalence in the women of Shanghai, China and its association with the severity of cervical neoplasia. Int J Clin Exp Pathol. 2018;11(9):4614-21.
  44. Anderson LA, O'Rorke MA, Wilson R, Jamison J, Gavin AT, Northern Ireland HPVWG. HPV prevalence and type-distribution in cervical cancer and premalignant lesions of the cervix: A population-based study from Northern Ireland. J Med Virol. 2016;88(7):1262-70. [DOI:10.1002/jmv.24447] [PMID]
  45. Ouh YT, Min KJ, Cho HW, Ki M, Oh JK, Shin SY, et al. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014-2016. J Gynecol Oncol. 2018;29(1):e14. [DOI:10.3802/jgo.2018.29.e14] [PMID] [PMCID]
  46. Chalabiani S, Nazari MK, Shabani M, Davoodi NR, Sarafnejad A, Amirzargar AAJAPJoCB. Retrospective analysis of prevalence of high-risk and low-risk Human Papillomavirus (HPV) genotypes in iranian women during 2013-2016. 2017;2(4):85-90. [DOI:10.31557/apjcb.2017.2.4.85-90]
  47. Sudenga SL, Torres BN, Silva R, Villa LL, Lazcano-Ponce E, Abrahamsen M, et al. Comparison of the natural history of genital HPV infection among men by country: Brazil, Mexico, and the United States. Cancer Epidemiology, Biomarkers & Prevention. 2017;26(7): 1043-52. [DOI:10.1158/1055-9965.EPI-17-0040] [PMID] [PMCID]
  48. Munoz N, Bosch FX, Castellsagué X, Díaz M, De Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. International journal of cancer. 2004;111(2):278-85. [DOI:10.1002/ijc.20244] [PMID]
  49. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121(3):621-32. [DOI:10.1002/ijc.22527] [PMID]
  50. Chan PK, Cheung TH, Li WH, Yu MY, Chan MY, Yim SF, et al. Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in Southern China. Int J Cancer. 2012;131(3):692-705. [DOI:10.1002/ijc.26404] [PMID]
  51. Huang S, Afonina I, Miller BA, Beckmann AM. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Int J Cancer. 1997;70(4):408-11. [DOI:10.1002/(SICI)1097-0215(19970207)70:43.0.CO;2-#]
  52. Ho C-M, Chien T-Y, Huang S-H, Lee B-H, Chang S-F. Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. Gynecologic oncology. 2006;102(1):54-60. [DOI:10.1016/j.ygyno.2005.11.035] [PMID]
  53. Sasagawa T, Basha W, Yamazaki H, Inoue M. High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol Biomarkers Prev. 2001;10(1):45-52.
  54. Zhang C, Park JS, Grce M, Hibbitts S, Palefsky JM, Konno R, et al. Geographical distribution and risk association of human papillomavirus genotype 52-variant lineages. J Infect Dis. 2014;210(10):1600-4. [DOI:10.1093/infdis/jiu310] [PMID] [PMCID]
  55. Xi LF, Koutsky LA, Castle PE, Edelstein ZR, Meyers C, Ho J, et al. Relationship between cigarette smoking and human papilloma virus types 16 and 18 DNA load. 2009;18(12):3490-6. [DOI:10.1158/1055-9965.EPI-09-0763] [PMID] [PMCID]
  56. Hooi DJ, Lissenberg-Witte BI, de Koning MN, Pinedo HM, Kenter GG, Meijer CJ, et al. High prevalence of high-risk HPV genotypes other than 16 and 18 in cervical cancers of Curaçao: implications for choice of prophylactic HPV vaccine. 2018;94(4):263-7. [DOI:10.1136/sextrans-2017-053109] [PMID] [PMCID]
  57. Jamshidi Makiani M, Minaeian S, Amini Moghaddam S, Moosavi SA, Moeini Z, Zamani V, et al. Relative frequency of human papillomavirus genotypes and related sociodemographic characteristics in women referred to a general hospital in Tehran, 2014-2015: A cross-sectional study. Int J Reprod Biomed. 2017;15(5):305-10. [DOI:10.29252/ijrm.15.5.305] [PMID] [PMCID]
  58. Vu LT, Bui D, Le HT. Prevalence of cervical infection with HPV type 16 and 18 in Vietnam: implications for vaccine campaign. BMC Cancer. 2013;13(1):53. [DOI:10.1186/1471-2407-13-53] [PMID] [PMCID]
  59. Coscia MF, Monno R, Ballini A, Mirgaldi R, Dipalma G, Pettini F, et al. Human papilloma virus (HPV) genotypes prevalence in a region of South Italy (Apulia). Ann Ist Super Sanita. 2015;51(3):248-51.
  60. Sohrabi A, Hajia M, Jamali F, Kharazi FJJoI, Health P. Is incidence of multiple HPV genotypes rising in genital infections? 2017;10(6):730-3. [DOI:10.1016/j.jiph.2016.10.006] [PMID]
  61. Yousefi Z, Aria H, Ghaedrahmati F, Bakhtiari T, Azizi M, Bastan R, et al. An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy. Front Immunol. 2021;12:805695. [DOI:10.3389/fimmu.2021.805695] [PMID] [PMCID]
Iranian Journal of Pathology
Volume 19, Issue 4
Autumn 2024
Pages 431-440

  • Receive Date 05 January 2024
  • Revise Date 31 January 2024
  • Accept Date 24 March 2024

Home

Guide for Authors

Submit Manuscript

Contact Us